UGT1A1 and hyperprolactinemia: Furthermore, UGT1A1 may also be potentially involved in the metabolic pathway of risperidone since an association between UGT1A1 genetic polymorphisms and risperidone-induced hyperprolactinemia has been established in a clinical study in Thailand (Hongkaew et al., 2018).